CRISPR - based gene editing

Search documents
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Globenewswire· 2025-08-07 11:30
Core Insights - Intellia Therapeutics reported strong operational progress and financial results for Q2 2025, highlighting advancements in its CRISPR-based therapies for hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis [1][2]. Operational Highlights - Enrollment in the Phase 3 MAGNITUDE trial for nexiguran ziclumeran (nex-z) in ATTR-CM is ahead of projections, with plans to expand total enrollment to approximately 1,200 patients [4][9]. - The company expects to complete enrollment in the MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) by the first half of 2026 [4]. - Randomization in the Phase 3 HAELO study for lonvoguran ziclumeran (lonvo-z) is anticipated to be completed in Q3 2025 [4][5]. - Intellia ended Q2 2025 with approximately $630.5 million in cash and equivalents, expected to fund operations into the first half of 2027 [4][10]. Financial Results - Collaboration revenue for Q2 2025 was $14.2 million, up from $6.9 million in Q2 2024, primarily due to cost reimbursements from Regeneron Pharmaceuticals [10]. - Research and development expenses decreased to $97.0 million in Q2 2025 from $114.2 million in Q2 2024, driven by lower employee-related costs and stock-based compensation [10]. - General and administrative expenses also decreased to $27.2 million in Q2 2025 from $31.8 million in Q2 2024 [10]. - The net loss for Q2 2025 was $101.3 million, an improvement from a net loss of $147.0 million in Q2 2024 [10][18]. Upcoming Events - Intellia will participate in several conferences in Q3 2025, including the Citi 2025 Biopharma Back to School Conference and the Wells Fargo Health Care Conference [10].
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
ZACKS· 2025-07-07 14:50
Core Viewpoint - Intellia Therapeutics (NTLA) has demonstrated significant stock performance, with a 29.8% increase over the past month, outperforming the industry and the S&P 500 index [1][7]. Company Performance - The company's stock performance is attributed to advancements in its pipeline development and increased interest in gene therapies following Eli Lilly's acquisition of Verve Therapeutics [3][4]. - Intellia is transitioning towards becoming a commercial-ready organization by the end of 2026 [9]. Pipeline Development - Intellia is advancing two late-stage in vivo candidates: nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) [4][8]. - Nex-z is currently undergoing two phase III studies, with enrollment in the MAGNITUDE 2 study expected to complete by 2026 and a potential biologics license application planned for 2028 [5][6]. - Lonvo-z is in the pivotal phase III HAELO study, with enrollment expected to complete by Q3 2025 and a regulatory filing planned for the second half of 2026 [8]. Competitive Landscape - Intellia faces competition from other companies utilizing CRISPR/Cas9 technology, such as CRISPR Therapeutics, which recently received approval for its gene-edited therapy, Casgevy [12][13]. - The company has decided to halt the development of its in vivo gene insertion candidate, NTLA-3001, and plans to reduce its workforce by nearly 27% in 2025 [13]. Financial Outlook - NTLA shares currently trade at a price/book ratio of 1.43, below the industry average of 3.13 [14]. - The Zacks Consensus Estimate for NTLA's loss per share has narrowed for both 2025 and 2026, indicating a potential improvement in financial performance [16]. Conclusion - Intellia's recent stock rally is promising, but the lack of an approved product remains a significant challenge [17]. - The successful development of its pipeline candidates is crucial for the company's future [17][18].